In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


GSK's Risk-Sharing Deals to Compete with In-House R&D

Executive Summary

Convinced of the merits of its Center of Excellence set-up across R&D, GSK has built another unit focused exclusively on external drug discovery, with a broader, risk-sharing deal-style. The aim is to expand R&D without increasing the company's size.

Related Content

Dealmaking When Pharma's the Only Game in Town
GSK Tries to Mimic Real-World Biotech
Payback: Making Innovation Count in Uncertain Times
Not-For-Profit Makes Business Sense, Too
Merck's Deal Focus
AstraZeneca Joins the In-Licensing Game
How Big Pharma is Tackling the R&D Problem
How Big Pharma is Tackling the R&D Problem
Theravance: Having Cake and Eating It
Theravance: Having Cake and Eating It


Related Companies

Related Deals




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts